RecruitingNot Applicable

Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer

Belgium40 participantsStarted 2015-09

Plain-language summary

The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to: generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer * perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors * evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options * evaluate biomarkers of drug sensitivity * study primary and secondary (acquired) resistance in these models

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent * Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available * Follow-up data should be available * Patients with recurrent disease are allowed * Written informed consent

What they're measuring

Identification of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with immunohistochemistry (KI67) on FFPE (fixation followed by paraffin embedding) slides

Timeframe: 10 years

Trial details

NCT IDNCT02572778

SponsorCliniques universitaires Saint-Luc- Université Catholique de Louvain

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12

Contact for this trial

Aline Gillain, MedSciences

00322764 aline.gillain@uclouvain.be

View on ClinicalTrials.gov More Squamous Cell Carcinoma of the Head and Neck trials